Clinical Research Directory

A Prospective muLticEnter Registry in chrONic coronARy synDrOme

Sponsor: University of Roma La Sapienza

Summary

In patients with chronic coronary syndrome (CCS), clopidogrel has a class I/A indication in patients undergoing elective percutaneous coronary intervention (PCI). Although unproven, the possibility exists that clopidogrel does not yield an optimal platelet inhibition in multiple real-world scenarios that challenge current recommendations. The aim of this prospective observational study io assess in a consecutive unselected series of patients with CCS undergoing elective PCI the frequency of the following real world clinical scenarios: * No pretreatment at time of PCI ('naïve') * Evidence of incomplete responsiveness to clopidogrel * Indication to a complex PCI. We expect to demonstrate: * A not negligible proportion of patients with CCS are 'naïve' at time of elective PCI in clinical practice and require a rapid onset of P2Y12 inhibition. * A substantial proportion of patients with CCS who are treated with clopidogrel prior to elective PCI have high platelet responsiveness at time of the procedure. * A complex PCI is performed in a substantial proportion of patients with CCS.

Official title: Real-world Patterns of Anti-platelet Management in Stable Angina Patients Undergoing Percutaneous Coronary Intervention

Key Details

Conditions

Interventions